Identification and location of the structural glycoproteins of a tissue culture-adapted turkey enteric coronavirus

S. Dea, S. Garzon, and P. Tijssen

1 Centre de Recherche en Médecine Comparée Université du Québec, Institut Armand-Frappier, Laval-des-Rapides, Québec, and
2 Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada

Accepted March 27, 1989

Summary. The Minnesota strain of turkey enteric coronavirus (TCV) was grown on a human rectal tumor (HRT-18) cell line in the presence of radiolabeled amino acids and glucosamine to analyse virion structural proteins. In addition to the 52,000 unglycosylated nucleocapsid protein, three major glycoprotein species were found to be associated with the viral envelope. A predominant glycosylated protein with a molecular weight of 22–24,000 represented the transmembrane matrix protein. Larger glycoproteins with apparent molecular weights of 180–200,000 (gp 200), 120–125,000 (gp 120) and 95–100,000 (gp 100) were associated to the characteristic large bulbous projections (peplomers) located at the surface of the virion. The gp 100 and gp 120 species apparently arose from a proteolytic cleavage of gp 200, as suggested by digestion studies with trypsin and chymotrypsin. An additional large glycoprotein with mol.wt. of 140,000 (gp 140), that behaved as a disulfide-linked dimer of a 66,000 molecule, was found to be associated to granular projections located near the base of the large peplomers. Digestion studies with trypsin, bromelain and pronase demonstrated that gp 140 was related to the hemagglutinating activity of the virus. An inner membranous sac or tongue-shaped structure could be visualized in the interior of the viral particles following treatment with pronase. In contrast, trypsin or chymotrypsin treatments resulted in evaginations ("budding") on the virus surface. Progeny viral particles produced in TCV-infected cell cultures in the presence of tunicamycin lacked both types of surface projections, as demonstrated by electron microscopy and electrophoresis. The matrix protein also appeared to be reduced to its unglycosylated form, concomitant with a considerable loss of its antigenicity. Thus, with respect to its morphological and biochemical characteristics, TCV resembles viruses belonging to the group of mammalian hemagglutinating coronaviruses, but differs in that both types of envelope glycoproteins are N-glycosylated as in case of the avian infectious bronchitis virus.
Introduction

Most coronaviruses studied in detail to date can be described as having three or four unique major structural proteins [29, 34]. A predominant phospho-rylated nucleocapsid (N) protein with a molecular weight ranging from 50,000 to 60,000 is associated with the non-segmented, positive-stranded RNA genome. There are two major virus-encoded envelope proteins: a transmembrane glycoprotein with an approximate mol.wt. of 25–30,000 acting as a matrix protein (E1) and the peplomer protein (E2), a glycoprotein with a mol.wt. of 170,000–200,000 that makes up the large surface projections of the virus. The peplomer protein E2 often is posttranslationally cleaved by host-cell proteases into two subunits with mol.wts. of 85–100,000 [3, 19, 35]. The E2 glycoprotein is responsible for virus attachment and cell membrane fusion, and elicits the production of virus-neutralizing antibodies [9, 18, 20, 38]. The hemagglutinin of the hemagglutinating mammalian coronaviruses is made of an additional glycoprotein with a mol.wt. of 130–140,000 comprized of disulfide-linked 65,000 subunits [8, 9, 13, 15].

Many enteric coronaviruses are difficult to grow in tissue cultures; consequently, little is known about their molecular and antigenic structure [29, 30]. The turkey enteric coronavirus (TCV), recognized as one of the major causative agents of epidemic diarrhea in turkey poults, is an example of this group [11, 22]. Previous attempts to adapt TCV isolates to different types of cultured chicken and turkey embryonic cells were unsuccessful [25, 26]. The prototype Minnesota strain was maintained by oral inoculation and intestinal infection of one-day old turkey poults, or by inoculation into the amniotic cavity of embryonating turkey or hen eggs [10, 26]. Our previous studies on the morphology and some of the biological activities of egg-adapted TCV isolates have revealed the presence of two morphologically distinct types of peplomers at the surface of the TCV virion, and the virus also possesses an hemagglutinating activity [5, 6]. Low quantity of material obtained at the end of the preparation of “pure virus” and residual host-cell contaminating proteins of egg-adapted virus raised difficulties in distinguishing specific viral components from degraded or host proteins [6]. TCV isolates purified from the intestinal contents of turkey embryos were resolved into four to seven major polypeptides ranging in molecular weights from 27,000 to 180,000 and were identified as viral components on the basis of their reactivity with specific antisera [6]. The exact nature of these polypeptides and their location on the TCV virion remained to be determined.

This report deals with the polypeptide structure of a tissue culture-adapted TCV isolate [7]. We identified three major glycoproteins corresponding to the matrix, the peplomer, and the hemagglutinin of the TCV virion by radiolabeling, or by adding glycosylation inhibitors during virus production, or by partial protease digestion of the virions. Further, electron microscopy of purified protease-treated virus allowed us to obtain more information on the morphological characteristics of this avian coronavirus.
Turkey enteric coronavirus proteins

Materials and methods

Virus and cell cultures

The prototype egg-adapted Minnesota strain of TCV (obtained from Dr. B. S. Pomeroy, College of Veterinary Medicine, Univ. of Minnesota, St. Paul, MN) was used in these studies [10]. The virus was serially propagated, in presence of trypsin, in confluent monolayers of the human rectal tumor cell line HRT-18, as previously described [7]. The growth of the virus was measured by titration of clarified culture medium using an end-point dilution procedure and the calculation of TCID50, according to Reed and Muench [27]. Viral stocks were prepared from passages 3 to 5 by infecting cells at a multiplicity of 0.1 to 1.0 TCID50 per cell.

Virus purification

The virus was purified from the supernatant fluids of infected cell cultures by differential and isopycnic ultracentrifugation on sucrose gradients, as previously described [6]. The purified virus sedimented to a buoyant density of 1.18-1.20 g/ml, as determined from the coincidental peak of hemagglutinating activity and optical density at 280 nm. Collected virus was diluted in TBS and pelleted by ultracentrifugation for 2 h at 24,000 rpm in a Beckman SW 27.1 rotor. The viral material was gently suspended in TBS, divided into aliquots, and quickly frozen at —70 °C. Protein concentration in purified viral suspensions was determined by the method of Bradford [2].

Hemagglutination assay

The hemagglutination assay was performed using rat erythrocytes, as described previously [5].

Enzymatic treatments of purified virus

Aliquots of purified virus were incubated with 100 µg/ml or 1,000 µg/ml of either trypsin, α-chymotrypsin or pronase in TMEN (50 mM Tris-maleate, 1 mM EDTA, 150 mM NaCl, pH 6.0) buffer for 30, 45, 60, or 90 min at 37 °C. In case of trypsin treatment, the digestion reactions were stopped by adding an equal amount of soybean trypsin inhibitor and further incubated 30 min at 37 °C. For treatment with bromelain, purified virus was incubated with 1.3 mg/ml of the enzyme in TMEM containing 5 mM dithiothreitol for 1 to 3 h at 37 °C. After enzymatic treatments, the virus was immediately subjected to isopycnic centrifugation, tested for residual HA activity, and analyzed by SDS-PAGE.

Antiserum

An anti-TCV hyperimmune serum was obtained after immunization of rabbits with the purified egg-adapted virus [5]. The specificity of the antiserum has been confirmed by immunoelectron microscopy and hemagglutination inhibition [6].

Radioisotopic labeling of virion structural proteins

Confluent monolayers of HRT-18 cells grown in 150 cm²-tissue culture flasks (Corning) were infected at a multiplicity of 1 TCID 50/cell. After adsorption of the virus for 1 h, the monolayers were further incubated at 41 °C with serum-free medium containing 10 U/ml of trypsin. Tunicamycin, at concentrations of 0.1 to 1.0 µg/ml, or sodium monensin, at concentrations of 0.1 to 2.5 µM, were added to maintenance media in glycosylation-inhibition experiments. At 6 to 9 h post-infection (p.i.), the medium was removed and 15 mL of the appropriate medium, with or without glycosylation inhibitors, and the radioisotopic
compounds were added. Viral proteins were labeled by addition of 250μCi of
[35S]methionine or 400μCi of 3H-labeled amino acids (a mixture of L-lysine, L-leucine and L-alanine) per flask in methionine-free RPMI medium or in MEM containing 10 percent of the normal concentration of leucine and lysine, respectively. Viral glycoproteins were labeled with D-[6-3H]glucosamine hydrochloride at 25μCi/ml in MEM containing 20 percent of the normal concentration of glucose. Supernatants containing radiolabeled virus were harvested at 48 to 72 h p.i.

**Immunoprecipitation and Western immunoblotting**

Immunoprecipitation experiments with purified radiolabeled protease-treated or untreated virus were done essentially as described by Orvell et al. [24], using rabbit anti-TCV hyperimmune serum. After a 3 h incubation at room temperature, the immune complexes were adsorbed to protein A-Sepharose (Pharmacia), and desorbed by denaturation prior to electrophoresis by boiling for 3 min in the sample buffer [16].

Western immunoblotting assays were done according to Deregt and Babiuk [8].

**Polyacrylamide gel electrophoresis**

The discontinuous buffer gel system of Laemmli was used [16]. Samples were mixed with equal volumes of double strength sample buffer with or without 5 percent 2-mercaptoethanol, boiled for 3 min, and clarified at 10,000 × g for 15 min before electrophoresis in 8.5 or 10 percent SDS-polyacrylamide slab gels, as previously described [6]. High and low molecular weight marker proteins or 14C-methylated marker proteins were run on each gel to allow molecular weight estimates of viral proteins. Polypeptide bands were revealed either by silver staining [21] or by fluorography (“Amplify”, Amersham). Dried gels were autoradiographed on Kodak X-OMAT RP films at −70°C.

**Electron microscopy**

Concentrated, gradient-purified, and protease-treated virions were negatively stained with 2% sodium phosphotungstate, pH 7.0, and examined by EM, as described previously [4].

**Chemicals and isotopes**

Tunicamycin (TM), sodium monensin, phenylmethylsulfonyl fluoride (PMSF), aprotinin, bromelain from pineapple, and pronase from *Streptomyces griseus* were purchased from Boehringer-Mannheim Canada Ltd., Dorval, Quebec. Stock solutions of TM (2 mg/ml) and sodium monensin (1,000 μM) were prepared in dimethylsulfoxide and in methanol, respectively. These inhibitors were also purchased from Calbiochem, La Jolla, CA. Bovine pancreatic trypsin (TPCK treated, 12,300 units/mg) and α-chymotrypsin (type VII, 49 units/mg), soybean trypsin inhibitor and 4-chloro-1-naphthol were purchased from Sigma Chemical Co., St. Louis, MO. Reagents for SDS-PAGE were purchased from BIO-RAD Laboratories, Richmond, CA. Protein A Sepharose CL-4B and molecular weight marker proteins were purchased from Pharmacia, Uppsala, Sweden. L-[35S]methionine (1,120 Ci/m mole) and mixture of 14C-methylated marker proteins were purchased from Amersham Searle Co., Oakville, Ontario. D-[6-3H]glucosamine hydrochloride (25–30 Ci/m mole), L-[3H]leucine (50 Ci/m mole), L-[3H]alanine (44 Ci/m mole), and L-[3H]lysine (48 Ci/m mole) were purchased from ICN Biochemical Canada Ltd, Montreal, Quebec.
Table 1. Virus purification and recovery of virus infectivity

| Virus sample                              | Total infectivity (TCID₅₀ units) | Volume (ml) | (%) Recovery | Total protein (mg) | TCID₅₀/µg protein | Purification* factor |
|--------------------------------------------|-----------------------------------|-------------|--------------|--------------------|-------------------|---------------------|
| Clarified tissue culture fluid             | $5.60 \times 10^{10}$            | 400         | 100          | 320                | $0.017 \times 10^7$ | 1                   |
| Viral precipitate (> 35% sucrose)          | $4.67 \times 10^{10}$            | 12          | 83.4         | 31.2               | $0.15 \times 10^7$  | 8.8                 |
| Interface from discontinuous (30–50%) sucrose gradient | $3.55 \times 10^{10}$            | 2           | 63.4         | 4.6                | $0.77 \times 10^7$  | 45.3                |
| Pelleted virus from continuous sucrose gradient fractions 1.18–1.20 g/ml | $3.16 \times 10^{10}$            | 1           | 56.4         | 1.5                | $2.11 \times 10^7$  | 124.1               |

* Purification factor is calculated by estimating total infectivity/µg protein at each stage of purification and dividing by the estimate obtained from clarified tissue culture fluid.
Results

Viral purification

Previous studies on the cell cultivation of the Minnesota strain of TCV have revealed an effective production of the virus in HRT-18 cells, provided trypsin was added to the culture medium [7]. High yields of viral infectivity, ranging from $10^8$ to $10^{10}$ TCID50/ml, were recovered after less than 3 or 4 successive passages. HA titers rose also with the number of passages and, with rat erythrocytes, ranged from $1:128$ to $1:2,048$. Data from a representative virus purification experiment (Table 1) show 400-fold reduction in volume and greater than 200-fold decrease in total protein, with 50 to 60% recovery of virus infectivity. The procedure allowed the preparation of about 1.5 mg of approximately 125-fold purified virus from $2.5 \times 10^8$ cells (specific infectivity averaged $2 \times 10^7$ TCID50/µg protein). Three visible bands were obtained following centrifugation in the continuous sucrose gradient, but infectivity and HA activity were restricted to the band corresponding to a buoyant of $1.18-1.20$ g/ml (Fig. 1A). The corresponding fractions contained viral particles with a morphology consistent with that of coronaviruses. The majority of the viral particles possessed surface projections of two distinct sizes (Fig. 1B).

Structural polypeptides of TCV

Analysis by SDS-PAGE under non-reducing conditions of purified $[^{35}S]$methionine- or $^3$H-amino acids-labeled TCV revealed consistently at least four major and two minor polypeptide species. The results were essentially the same for virus cultivated in the presence or in the absence of trypsin (Fig. 2).

![Fig. 1A](image1.png)  ![Fig. 1B](image2.png)

Fig. 1A Isopycnic purification of the Minnesota strain of TCV in a sucrose gradient after its fourth passage in HRT-18 cells. B Electron micrograph of purified viral particles with a double fringe of surface peplomers. The arrow indicates the fringe of small granular projections. Bar: 100 nm
Turkey enteric coronavirus proteins

Fig. 2. SDS-PAGE analysis of TCV structural polypeptides. The Minnesota strain of TCV was cultivated in HRT-18 cells in the presence (+) or the absence (−) of trypsin and labeled with either $[^{35}S]$methionine (1, 2, 6, 7), $^3$H-amino acids (3, 4, 8, 9), or $[^{3}H]$glucosamine (5, 10). Purified virus was electrophoresed after solubilization with sample buffer in the absence (1–5) or presence (6–10) of 5 per cent 2-ME. The acrylamide concentration in the gel was 10 per cent. Positions of molecular weight standards are shown on the left. ▶ 120,000 and 140,000 glycoproteins. a Glycosylated polypeptide with a mol.wt. in excess of 200,000

| Position (KDa) | 14.3K | 30K | 43K | 66K | 97.4K | 200K |
|---------------|-------|-----|-----|-----|-------|------|
| gp200         |       |     |     |     |       |      |
| gp140         |       |     |     |     |       |      |
| gp120         |       |     |     |     |       |      |
| gp100         |       |     |     |     |       |      |
| gp66          |       |     |     |     |       |      |
| p52           |       |     |     |     |       |      |
| (46)          |       |     |     |     |       |      |
| (36-38)       |       |     |     |     |       |      |
| (32)          |       |     |     |     |       |      |
| gp24          |       |     |     |     |       |      |
| p22           |       |     |     |     |       |      |
| p20           |       |     |     |     |       |      |

The major components were estimated to possess molecular weights of 140,000, 95–100,000, 52,000, and 22–24,000, while two minor components had mol.wts. of 180–200,000 and 120–125,000, respectively (Fig. 2, lanes 1 to 5). The 22–24,000 mol.wt. polypeptide was characteristically observed as a broad band or as a group of 2 to 3 closely migrating bands. In addition, three additional polypeptide species with mol.wt. of 32,000, 36–38,000, and 44–46,000, migrating as bands with varying intensities, were irregularly detected. From these three polypeptides, only the 44–46,000 mol.wt. species could be resolved from the immunoprecipitates obtained after incubation with anti-TCV rabbit hyperimmune serum (Fig. 3C). Labeling with $[^{3}H]$glucosamine revealed that the 180–
200,000, 140,000, 120–125,000, 95–100,000, 44–46,000, and 22–24,000 mol.wts. species were glycosylated, and hence were designated gp200, gp140, gp120, gp100, gp46, and gp24 (Fig. 2, lanes 5 and 10). Under these conditions, the gp200 species was usually revealed as a major band. An additional glycosylated polypeptide (designated as a in Fig. 2) with a mol.wt. in excess of 200,000 was identified with [3H]glucosamine-labeled virus.

In the presence of 2-mercaptopethanol, gp140 could no longer be detected; instead a new glycosylated polypeptide with an estimated mol.wt. of 66,000 was observed (Fig. 2, lanes 6 to 10). These results were also confirmed by immunoprecipitation (data not shown) and Western immunoblotting experiments (Fig. 3). This suggested that gp140 is a disulfide-linked dimer of two smaller gp66 species.

**Location and biological properties of TCV structural proteins**

To determine the location of the TCV glycoproteins, aliquots of purified virus stocks were mock-digested or digested with pronase, trypsin, α-chymotrypsin or bromelain, repurified by isopycnic sedimentation, and analyzed by EM and SDS-PAGE (Figs. 3 and 4). Protease-treated TCV was also tested for residual hemagglutinating activity (Table 2).

Virions treated with pronase, at the concentration of 1 mg/ml, lost their hemagglutinating activity after 45 min (Table 2), coincidentally with the disappearance of the high-molecular-weight glycoproteins (gp200, gp140/66, gp120, and gp100) from the gel (Fig. 3A). Examination by EM of repurified particles showed that after 30 min of digestion, only the fringe of small granular projections was still present on the virion surface (Fig. 4a). After 45 min of digestion, the p52 and the 22–24,000 mol.wt. polypeptides were the predominant species remaining (Fig. 3A, lanes 3–5), and the particles appeared relatively smooth (Fig. 4b).

Time exposure of TCV to pronase also transformed the viral envelope, making it permeable to phosphotungstate, and resulted in progressively different...
Turkey enteric coronavirus proteins

A  B

C  D

<diagram>

<diagram>

<diagram>

<diagram>
types of viral particles. The presence of an inner fold of the viral envelope was commonly observed after a 45 min exposure to the enzyme, giving rise to the characteristic tongue-like structure described for several coronaviruses [1]. After a longer exposure (75 to 90 min), the center of the viral particles was densely stained (Fig. 4c) and numerous ghost-like structures were found.
Incubation for 1 hour with either trypsin or α-chymotrypsin, at concentrations up to 1 mg/ml, did not alter the hemagglutinating activity of TCV (Table 2). However, complete or nearly complete disappearance of the gp200 species from the gel, concomitant with a slight increase in the amounts of the gp100 and gp120 species, was observed (Fig. 3B, C). The other structural glycoproteins appeared resistant to both enzymes. Trypsin-treated virions maintained both types of surface projections at concentrations lower than 100 μg/ml, but apparently lost their large peplomers at higher concentrations (Fig. 4e). Treatment with α-chymotrypsin resulted in an apparent enlargement in the diameter of the tip of the larger projections, of which only a few were retained at the surface of the virions (data not shown). Evaginations of the internal tongue-shaped structure, which did not possess the characteristic club-shaped projections of the outer membrane, was often observed following treatments with both enzymes (Fig. 4d, e).

Digestion of TCV with bromelain for two hours did not alter the hemagglutinating activity of the virus (Table 2), but caused the loss of the high mol.wt.

| TCV polypeptides | Treatments | Trypsin μg/ml | Chymotrypsinα | Pronaseα | Bromelainα | Tunicamycinα |
|------------------|------------|---------------|---------------|----------|------------|--------------|
| gp 180-200       | ++         | -             | -             | -        | -          | -            |
| gp 140           | ++         | ++            | ++            | -        | ++         | -            |
| gp 120           | ++         | ++            | +             | -        | -          | -            |
| gp 100           | ++         | ++            | ++            | -        | -          | -            |
| gp 66            | ++         | ++            | ++            | -        | ++         | -            |
| p52              | ++         | ++            | ++            | ++       | +          | +            |
| gp 44-46         | ++         | ++            | ++            | +       | +/−        | −            |
| gp 24-26         | ++         | ++            | ++            | +/-      | +/−        | −            |
| p 20             | ++         | ++            | ++            | ++       | +          | +/−          |
| HA activity      | ++         | ++            | ++            | +        | +          | +            |

**Table 2.** Hemagglutinating activity and TCV polypeptides detected after treatment with proteases and tunicamycin

* TCV polypeptides detected by Western-immunoblotting analysis of sucrose gradient-purified untreated or treated virus
  * Tunicamycin was added to the culture medium of TCV-infected HRT-18 cells after the adsorption period and purified extracellular virus was harvested at 24 h post-infection
  * Purified TCV was treated for 1 h at 37 °C with trypsin and chymotrypsin, and for 3 h at 37 °C with bromelain
  - Absent
  + Barely detectable
  + Moderately affected
  ++ Intensity comparable to untreated virus
glycoproteins, except gp140 or gp66, when virus was electrophoresed under reducing conditions (Fig. 3C, lanes 3 and 4). This treatment also left the internal p52 protein intact, but reduced the amounts of gp24, concomitant with the disappearance of the 44,000 to 46,000 mol.wt. species (Fig. 3C, D). Although a decreased amount of p52 was noticed in silver-stained gels after a 3 h treatment with the enzyme (Fig. 3B, lane 3), it was still strongly evident following Western-immunoblotting with the anti-TCV serum, as well as the gp140 or gp65 species (Fig. 3D, lanes 1 to 3).

Examination by EM of repurified particles, after treatment with bromelain for 1 or 2 h, showed a progressive loss of the large bulbous peplomers, but a persistence of small granular projections, without any apparent damage to the particles themselves (Fig. 4f). After a longer exposure to the enzyme (3 h), only a few viral particles, which possessed only the small granular projections, were recovered from the sucrose gradient fractions at a buoyant density corresponding to that of the original virus. Numerous ghost-like or membranous structures were observed in fractions corresponding to sucrose densities of 1.23–1.26 g/ml.

**Fig. 5.** Structural proteins and morphology of TCV particles after cultivation in the presence of tunicamycin (TM). TCV-infected HRT-18 cells were cultivated in the presence of TM and [35S] methionine was added to the medium at 6 h after infection. After a further incubation of 12 h, viral particles were isolated from the culture media, purified by ultracentrifugation on sucrose gradients, examined by EM and analyzed in 10% SDS-polyacrylamide gels in the absence of 2-ME. **A, B** Autoradiographs (A) and immunoblotting profiles (B) of TCV after cultivation in the presence of 0.1 (1, 3) and 0.5 (2, 4) μg/ml of TM. **V** Untreated virus. **C** Released virions from TM-treated (1 μg/ml) infected cells were devoid of surface projections. Bar: 100 nm
Turkey enteric coronavirus proteins 233

Small granular projections were still present on the surface of the damaged viral particles (data not shown).

Effects of glycosylation inhibitors on the synthesis of envelope-glycoproteins

Virus purified from the supernatant fluids of TCV-infected cell cultures, cultivated in the presence of 0.5 to 1.0 μg/ml of tunicamycin, lacked both infectivity and hemagglutinating activity (Table 2). The extracellular viral particles were devoid of both types of surface projections (Fig. 5C). Cultivation in the presence of sodium monensin at concentrations up to 2.5 μM neither affected the virulence of the virus, nor changed the morphology of the extracellular progeny viral particles (data not shown).

These purified viral preparations were analyzed together with virus from untreated cell cultures by SDS-PAGE under non-reducing conditions and by Western immunoblotting (Fig. 5). Results indicated that high mol.wt. structural glycoproteins could no longer be detected following tunicamycin treatment of TCV-infected cells. The gp24 species was still resolved in the gels after silver staining and in autoradiographs after immunoprecipitation (Fig. 5A), but with a slightly higher mobility. It was no longer detectable by Western immunoblotting (Fig. 5B). A concomitant decrease in the amounts of the gp44 species was noted in both assays.

Discussion

The tissue culture-adapted Minnesota strain of TCV was grown in the presence of radiolabeled amino acids and glucosamine for the purpose of obtaining further information on the virion structural proteins. The structural nature of the polypeptides resolved by SDS-PAGE of purified virus was confirmed by Western immunoblotting and immunoprecipitation experiments, using anti-TCV hyperimmune serum previously obtained from immunization of rabbit with original egg-adapted virus. Four major viral protein species were identified and their location on the virion was deduced from digestion studies using various proteolytic enzymes. The TCV structural proteins consist of three glycoproteins of 180–200,000, 140,000, and 24,000 which were shown to correspond to the peplomer, hemagglutinin and matrix proteins, and a predominant unglycosylated 52,000 species that apparently represents the nucleocapsid protein. A similar polypeptide pattern has been described previously with virus purified from the intestinal contents of turkey embryos [6]. Polypeptide species of 72–75,000, and 45,000 earlier identified were probably host-cell contaminating proteins, or degradation products of the viral components resulting from their digestion by intestinal proteases. The largest virion glycoproteins of TCV thus appear to differ fundamentally from the largest glycoproteins of the well-characterized avian infectious bronchitis virus (IBV), an antigenically unrelated coronavirus [17, 26, 37]. The presence of additional short granular projections on the surface of the TCV virion, and an hemagglutinin glycoprotein that
appeared as a dimer of two smaller 65–70,000 molecules, are features that have been described so far only for viruses belonging to the group of mammalian hemagglutinating coronaviruses [13, 15, 36].

Our studies further showed that the virion 180–220 K peplomer glycoprotein of TCV, like the 180 to 200 K species of MHV, BCV, and IBV, possesses a trypsin sensitive site, the cleavage of which yields two subunits with apparent mol.wt. of 100 K and 120 K [3, 8, 35]. The glycosylated species with a mol.wt. in excess of 200 K probably correspond to a multimeric form of the peplomeric glycoprotein as it was previously described for the human OC43 strain and BCV [13, 15], and for IBV [31]. Proteolytic cleavage of the TCV peplomer protein appeared to occur quite efficiently, as gp100 and gp120 were the predominant forms resolved by SDS-PAGE. This also appears to be true for BCV and HCV OC43 [13, 14]. The degree of posttranslational cleavage of the MHV-A59 strain was found to be a function of host cell type [12]. Although, we did not investigate the susceptibility of the TCV gp200 in different cell types, it was previously found that the virus could induce polykaryocytosis in HRT-18 cells only if trypsin was added to the maintenance medium. Addition of trypsin to the medium of TCV-infected primary chicken or turkey embryo kidney cell lines did not permit expression of the cytopathogenicity of the virus. The trypsin cleavage of gp200 of TCV seemed thus necessary for the acquisition of the fusion activity, and therefore for the infectivity of the virus, but host cell intrinsic factors are probably also involved. Similar findings were observed for MHV and BCV [32, 35], and with several strains of IBV [3] which do not form plaques unless trypsin is added to the overlay medium.

Treatment with different proteases to remove the external proteins of TCV showed that bromelain-, trypsin- and chymotrypsin-treated virus still hemagglutinated rat erythrocytes, whereas pronase completely destroyed this activity. The observation that bromelain treatment removed all glycoproteins from the virion except gp140, and that only small granular projections were retained on the particles or ghost-like structures, when TCV was subjected to long exposures, strongly suggested gp140 and small granular projections to correspond to the virion hemagglutinin. The association between small granular projections and the hemagglutinin also was demonstrated in cases of mammalian hemagglutinating coronaviruses [15, 36].

Pronase and bromelain also reduced the amount or antigenicity of gp24. Similar to findings with other coronaviruses [13, 14, 34], these enzymes may have removed a portion corresponding to the terminal glycosylated region of the matrix protein which is exposed on the outer surface of the viral envelope, while a larger non-glycosylated region is protected within the envelope. The disappearance of gp46 from the gel following digestion with pronase and bromelain, concomitant with a reduction in the amount of gp24, suggested the close relationship between these two viral components. The gp46 species may represent a dimer of the matrix protein as demonstrated for BCV and HCV OC43 [9, 13]. Similarly, a 160 K unglycosylated polypeptide was occasionally
revealed by Western immunoblotting and immunoprecipitation. It may correspond to a polymer, possibly a trimer, of the nucleocapsid protein as suggested for BCV [8, 9] and HCV OC43 [13] on the basis of its reactivity with anti-N antibodies.

In the presence of TM, non-infectious TCV virions lacking both types of surface peplomers were produced and released by infected cells. Biochemical data confirmed the absence of the high mol.wt. glycoproteins (gp200/100, gp140/66) consistent with a glycosylation process that involves attachment of oligosaccharide side chains via N-glycosidic bonds to asparagine residues, as demonstrated for other coronaviruses [23, 34]. The matrix protein of TCV is apparently glycosylated by a similar process; following cultivation in the presence of TM, gp24 failed to react with the anti-TCV serum after Western immunoblotting and had a slightly higher mobility as demonstrated by immunoprecipitation. Our finding that gp24 was present after immunoprecipitation, but not after Western immunoblotting (Fig. 5A), may be explained by non-specific co-precipitation by the antiserum of viral proteins with high mutual affinity [33]. In contrast, for Western immunoblotting, to be visible proteins should be individually immunoreactive (i.e., sufficient amount and suitable conformation of epitopes). The inhibition of glycosylation of the matrix protein was also suggested by disappearance of gp46. In this respect, TCV resembles the avian infectious bronchitis virus [31], but differs from the mammalian coronaviruses MHV-A59 and BCV. The analogous protein of these mammalian coronaviruses undergoes O-linked glycosylation by a process which is resistant to TM and involves attachment of oligosaccharides to serine residues [8, 28].

The presence of an inner fold of the viral envelope, which could be evaginated following trypsin treatment and was devoid of the characteristic projections, and the presence of an internal tongue-like structure are in agreement with the structural model of coronavirus proposed by Almeida and Bingham [1]. No structures were seen inside the outer envelope after evagination or breakdown of the inner membrane, but a denser structure existed inside the intact viral particles (Fig. 4B). Whether this structure represents the nucleocapsid of TCV remains to be demonstrated.

Acknowledgements

This report was taken in part from a dissertation to be submitted by S.D. to the Department of Virology, Institute Armand-Frappier, University of Quebec, in partial fulfillment of the requirements for the Ph.D. degree. This research was supported in part by grants received from the Quebec Federation of Poultry Producers and the Conseil des recherches et services agricoles du Québec, and a fellowship to S.D. from the Medical Research Council of Canada.

References

1. Bingham RW, Almeida JD (1977) Studies on the structure of a coronavirus-avian infectious bronchitis virus. J Gen Virol 36: 495–502
2. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254
3. Cavanagh D, Davis PJ, Pappin DJC, Binns MM, Boursnell MEG, Brown TDK (1986) Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor polypeptide of IBV strains Beaudette and M41. Virus Res 4: 133–143
4. Dea S, Roy RS, Begin ME (1979) Counterimmunoelectrophoresis for detection of neonatal calf diarrhea coronavirus: methodology and comparison with electron microscopy. J Clin Microbiol 10: 240–244
5. Dea S, Marsolais G, Beaubien J, Ruppanner R (1986) Coronaviruses associated with outbreaks of transmissible enteritis (Bluecomb) of turkeys in Quebec: hemagglutination properties and cell cultivation. Avian Dis 30: 319–326
6. Dea S, Tijssen P (1988) Identification of the structural proteins of turkey enteric coronavirus. Arch Virol 99: 173–186
7. Dea S, Garzon S, Tijssen P (1988) Isolation and trypsin-enhanced propagation of turkey enteric (Bluecomb) coronaviruses in a continuous human rectal tumor (HRT-18) cell line. Am J Vet Res (in press)
8. Deregt D, Sabara M, Babiuk LA (1987) Structural proteins of bovine coronavirus and their intracellular processing. J Gen Virol 68: 2863–2877
9. Deregt D, Babiuk LA (1987) Monoclonal antibodies to bovine coronavirus: characteristics and topographical mapping of neutralizing epitopes on the E2 and E3 glycoproteins. Virology 161: 410–420
10. Deshmukh DR, Larsen CT, Pomeroy BS (1973) Survival of Bluecomb agent in embryonating turkey eggs and cell cultures. Am J Vet Res 34: 673–675
11. Deshmukh DR, Pomeroy BS (1977) Physicochemical characterization of a bluecomb coronavirus of turkeys. Am J Vet Res 35: 1549–1552
12. Frana MF, Behnke JN, Sturman LS, Holmes KV (1985) Proteolytic cleavage of the glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavages and cell fusion. J Virol 56: 912–920
13. Hogue BG, Brian DA (1986) Structural proteins of human respiratory coronavirus OC43. Virus Res 5: 131–144
14. King B, Brian DA (1982) Bovine coronavirus structural protein. J Virol 42: 700–797
15. King B, Potts BJ, Brian DA (1985) Bovine coronavirus hemagglutinin protein. Virus Res 2: 53–59
16. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
17. Lanser JA, Howard CR (1980) The polypeptides of infectious bronchitis virus (IBV-M41 strain). J Gen Virol 46: 349–361
18. Laude H, Chapsal JM, Gelli J, Labiau S, Grosclaude J (1986) Antigenic structure of transmissible gastroenteritis virus. I. Properties of monoclonal antibodies direct against virion proteins. J Gen Virol 67: 119–130
19. Lytjtes W, Sturman LS, Bredenbeek PJ, Charite J, Van der Zeijst BAM, Horzinek MC, Spaan WJM (1987) Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology 161: 479–487
20. Mockett APA, Cavanagh D, Brown TDK (1984) Monoclonal antibodies to the SI spike and membrane proteins of avian infectious bronchitis coronavirus strain Massachusetts M41. J Gen Virol 65: 2281–2286
21. Morrissey JH (1981) Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem 117: 307–310
Turkey enteric coronavirus proteins

22. Naqi SA, Panigrahy B, Hall CF (1975) Purification and concentration of viruses associated with transmissible (coronaviral) enteritis of turkeys (Bluecomb). Am J Vet Res 36: 548–552

23. Nieman H, Klenk HD (1981) Coronavirus glycoprotein E1, a new type of viral glycoprotein. J Mol Biol 153: 993–1010

24. Orvell C, Sheshberadaran H, Norrby E (1985) Preparation and characterization of monoclonal antibodies directed against four structural components of canine distemper virus. J Gen Virol 66: 443–456

25. Panigrahy B, Naqi SA, Hall CF (1973) Isolation and characterization of viruses associated with transmissible enteritis (Bluecomb) of turkeys. Avian Dis 17: 430–438

26. Pomeroy BS (1984) Coronavirus enteritis of turkeys. In: Holstad MS, Barnes HJ, Calnek BW, Reid WM, Yoder HW (eds) Disease of poultry, 8th edn. Iowa State University Press, Ames, pp 553–559

27. Reed LJ, Muench H (1938) A simple method of estimating fifty percent end points. Am J Hyg 27: 493–497

28. Rottier PJM, Horzinek MC, Van Der Zeijst BAM (1981) Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. J Virol 40: 350–357

29. Siddell S, Wege H, Ter Meulen V (1982) The structure and replication of coronaviruses. Curr Top Microbiol Immunol 99: 131–163

30. Siddell S, Wege H, Ter Meulen V (1983) The biology of coronaviruses. J Gen Virol 64: 761–776

31. Stern DF, Selfon BM (1982) Coronavirus proteins: structure and functions of the oligosaccharides of the avian infectious bronchitis virus glycoproteins. J Virol 44: 804–812

32. Storz J, Rott R, Kaluza G (1981) Enhancement of plaque formation and cell fusion of an enteropathogenic coronavirus by trypsin treatment. Infect Immun 31: 1214–1222

33. Sturman LS, Holmes KV, Behnke J (1980) Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid. J Virol 33: 449–462

34. Sturman LS, Holmes KV (1983) The molecular biology of coronaviruses. Adv Virus Res 28: 35–112

35. Sturman LS, Ricard CS, Holmes KV (1985) Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments. J Virol 56: 904–911

36. Sugiyama K, Ishikawa R, Fukuhara N (1986) Structural polypeptides of the murine coronavirus DVIM. Arch Virol 89: 245–254

37. Waday CN, Westaway EG (1981) Structural proteins and glycoproteins of infectious bronchitis virus particles labelled during growth in chick embryo fibroblasts. Intervirology 15: 19–21

38. Wege H, Dorries R, Wege H (1984) Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E2). J Gen Virol 65: 1931–1942

Authors’ address: P. Tijssen, Centre de Recherche en Médecine Comparée, Institut Armand-Frappier, 531, boulevard des Prairies, Laval-des-Rapides, Quebec H7V1B7, Canada.

Received February 2, 1989